TriSalus Life Sciences, Inc. Warrant
TLSIWStock
$0.81
Market Cap—
P/E—
Div yield—
Beta1.76
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-57.85%
Price vs S&P 500 (4W)1.97%
VGM Score35.98
Industry Peers — Surgical & Medical Instruments(141)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TLSIWTriSalus Life Sciences, Inc. Warrant | — | — | D | $0.81 |
| SYKStryker Corporation | C | C | D | $331.20 |
| MMM3M Company | C | F | B | $161.77 |
| BSXBoston Scientific Corp. | C | B | F | $44.62 |
| MDLNMedline Inc. Class A common stock | C | D | D | $41.11 |
| BDXBecton, Dickinson and Co. | B | C | B | $159.93 |
| DXCMDexCom, Inc. | C | B | C | $77.98 |
| RMDResMed Inc. | C | B | D | $202.76 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | $362.44 |
| SOLVSolventum Corporation | C | D | B | $81.70 |
| PENPenumbra, Inc. | F | C | B | $319.60 |
About
TriSalus Life Sciences develops drug delivery systems and immune-oncology therapeutics targeting difficult-to-treat liver and pancreatic cancers. The company markets PEDD (Pressure Enabled Drug Delivery) infusion systems, including its latest TriNav device with SmartValve technology, which are in clinical use today. It is also advancing nelitolimod (SD-101), an investigational agent designed to enhance immune response against hepatocellular carcinoma, pancreatic cancer, and other liver tumors.